Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 17/2/2020
SIETES contiene 92902 citas

 
 
 1 a 20 de 127 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Read RC, Baxter D, Chadwick DR, Faust SN, Finn A, Gordon SB, Heath P, Lewis DJM, Pollard AJ, Turner DPJ, Bazaz R, Ganguli A, Havelock T, Neal KR, Ikike IO, Morales-Aza B, Patel K, Snape MD, Williams J, Gilchrist S, Gray SJ, Maiden MCJ, Toneatto D, Wang H, McCarthy M, Dull PM, Borrow R. Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial. Lancet 2014;384:2123-31. [Ref.ID 98454]
2. Cita con resumen
Anónimo. (Bexsero) vaccin méningococcique B. Prescrire 2014;34:251-4. [Ref.ID 97432]
3.
Shaughnessy AF. Meningitis outbreak shines light on pharmacy practice. BMJ 2012;345:22. [Ref.ID 94084]
4. Cita con resumen
Roehr B. Vaccines rarely cause adverse events, Institute of Medicine finds. BMJ 2011;343:d5538. [Ref.ID 91897]
5. Cita con resumen
Lenzer J. Pfizer settles with victims of Nigerian drug trial. BMJ 2011;343:d5268. [Ref.ID 91894]
6.Tiene citas relacionadas
Molyneux E, Nizami SQ, Saha S, Huu KT, Azam M, Bhuta ZA, Zaki R, Weber MW, Qazi SA, for the CSF 5 Study Group. 5 versus 10 days of treatment with ceftriaxone for bacterial meningitis in children: a double-blind randomised equivalence study. Lancet 2011;377:1837-45. [Ref.ID 90854]
7.Tiene citas relacionadas
Snape MD, Kelly DF. Fine with five? Shorter antibiotic courses for childhood meningitis. Lancet 2011;377:1809-10. [Ref.ID 90841]
8.Enlace a cita original
Visintin C, Mugglestone MA, Fields EJ, Jacklin P, Murphy MS, Pollard AJ, on behalf of the Guideline Development Group. Management of bacterial meningitis and meningococcal septicaemia in children and young people: summay of NICE guidance. BMJ 2010;341:92-4. [Ref.ID 88874]
9.
Tan LKK, Carlone GM, Borrow R. Advances in the development of vaccines against Neisseria meningitidis. N Engl J Med 2010;362:1511-20. [Ref.ID 88302]
10.Tiene citas relacionadas
Haber P, Sejvar J, Mikaeloff Y, DeStefano F. Vaccines and Guillain-Barré syndrome. Drug Saf 2009;32:309-23. [Ref.ID 85764]
12.Tiene citas relacionadas
Theilen U, Wilson L, Wilson G, Qureshi S, Simpson D, on behalf of the Guideline Development Group. Management of invasive meningococcal disease in children and young people: summary of SIGN guidelines. BMJ 2008;336:1367-70. [Ref.ID 83272]
13. Cita con resumen
Anónimo. Nigeria files for extradition of drug trial officials. BMJ 2008;336:350. [Ref.ID 82215]
14.Tiene citas relacionadas
15.Tiene citas relacionadas
Snape MD, Perrett KP, Ford KJ, John TM, Pace D, Yu LM, Langley JM, McNeil S, Dull PM, Ceddia F, Anemona A, Halperin SA, Dobson S, Pollard AJ. Immunogenicity of a tretavalent meningococcal glycoconjugate vaccine in infants. A randomized controlled trial. JAMA 2008;299:173-84. [Ref.ID 82008]
16. Cita con resumen
Loewenberg S. Drug company trials come under increasing scrutiniy. Lancet 2008;371:191-2. [Ref.ID 81983]
17.
Anónimo. Steroids for bacterial meningitis in children?. Drug Ther Bull 2007;45:93-5. [Ref.ID 81698]
19.Tiene citas relacionadas
Gardner P. Prevention of meningococcal disease. The author replies. N Engl J Med 2007;356:525-6. [Ref.ID 79087]
20.Tiene citas relacionadas
Senanayake SN. Prevention of meningococcal disease. N Engl J Med 2007;356:525. [Ref.ID 79086]
Seleccionar todas
 
 1 a 20 de 127 siguiente >>